Elias, Rawad

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 1,169

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis

Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 218

Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 133

Aging, immune senescence, and immunotherapy: a comprehensive review

Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 96

Immune checkpoint inhibitors in older adults

Elias, R., Morales, J., Rehman, Y., & Khurshid, H. (2016) · Current Oncology Reports

Cancer Immunotherapy and BiomarkersFrailty in Older Adults

Cited by 59